-
Something wrong with this record ?
Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality
EP. Paschalis, S. Gamsjaeger, N. Hassler, A. Fahrleitner-Pammer, H. Dobnig, JJ. Stepan, I. Pavo, EF. Eriksen, K. Klaushofer,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Amino Acids metabolism MeSH
- Analysis of Variance MeSH
- Calcification, Physiologic drug effects MeSH
- Glycosaminoglycans metabolism MeSH
- Bone Matrix drug effects metabolism MeSH
- Humans MeSH
- Nanoparticles chemistry MeSH
- Porosity MeSH
- Osteoporosis, Postmenopausal drug therapy physiopathology MeSH
- Dietary Supplements * MeSH
- Spectrum Analysis, Raman MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Calcium pharmacology therapeutic use MeSH
- Vitamin D pharmacology therapeutic use MeSH
- Check Tag
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Prospective, controlled clinical trials in postmenopausal osteoporosis typically compare effects of an active drug with placebo in addition to vitamin D and calcium supplementation in both treatment arms. While clinical benefits are documented, the effect of this supplementation in the placebo arm and in clinical practice on bone material composition properties is unknown. The purpose of the present study was to evaluate these bone quality indices (specifically mineral/matrix, nanoporosity, glycosaminoglycan content, mineral maturity/crystallinity, and pyridinoline content) in patients that either received long-term vitamin D (400-1200IU) and calcium (1.0-1.5g) supplementation, or did not. We have analyzed by Raman microspectroscopy the bone forming trabecular surfaces of iliac crest in pre-treatment samples of a teriparatide study and the endpoint biopsies of the control arm obtained from the HORIZON trial. In general, the mineral/matrix ratio and the glycosaminoglycan (GAG) content was higher while nanoporosity, (a surrogate for tissue water content), the mineral maturity/crystallinity (MMC) and the pyridinoline (Pyd) content was lower in patients without long-term supplementation. Moreover, all indices were significantly dependent on tissue age. In conclusion, vitamin D and calcium supplementation is associated with altered mineral and organic matrix properties.
Dept of Internal Medicine Medical University Graz Austria
Endocrinology Dept Oslo University Hospital Norway
Institute of Rheumatology Faculty of Medicine 1 Charles University Prague Czech Republic
Thyroid Endocrinology and Osteoporosis Institute Graz Austria
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016924
- 003
- CZ-PrNML
- 005
- 20180521123028.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bone.2016.11.002 $2 doi
- 035 __
- $a (PubMed)27826025
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Paschalis, E P $u Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK, AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Heinrich Collin Str. 30, A-1140, Vienna, Austria. Electronic address: lpaschalis@gmx.net.
- 245 10
- $a Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality / $c EP. Paschalis, S. Gamsjaeger, N. Hassler, A. Fahrleitner-Pammer, H. Dobnig, JJ. Stepan, I. Pavo, EF. Eriksen, K. Klaushofer,
- 520 9_
- $a Prospective, controlled clinical trials in postmenopausal osteoporosis typically compare effects of an active drug with placebo in addition to vitamin D and calcium supplementation in both treatment arms. While clinical benefits are documented, the effect of this supplementation in the placebo arm and in clinical practice on bone material composition properties is unknown. The purpose of the present study was to evaluate these bone quality indices (specifically mineral/matrix, nanoporosity, glycosaminoglycan content, mineral maturity/crystallinity, and pyridinoline content) in patients that either received long-term vitamin D (400-1200IU) and calcium (1.0-1.5g) supplementation, or did not. We have analyzed by Raman microspectroscopy the bone forming trabecular surfaces of iliac crest in pre-treatment samples of a teriparatide study and the endpoint biopsies of the control arm obtained from the HORIZON trial. In general, the mineral/matrix ratio and the glycosaminoglycan (GAG) content was higher while nanoporosity, (a surrogate for tissue water content), the mineral maturity/crystallinity (MMC) and the pyridinoline (Pyd) content was lower in patients without long-term supplementation. Moreover, all indices were significantly dependent on tissue age. In conclusion, vitamin D and calcium supplementation is associated with altered mineral and organic matrix properties.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a aminokyseliny $x metabolismus $7 D000596
- 650 _2
- $a analýza rozptylu $7 D000704
- 650 _2
- $a kostní matrix $x účinky léků $x metabolismus $7 D001857
- 650 _2
- $a fyziologická kalcifikace $x účinky léků $7 D002113
- 650 _2
- $a vápník $x farmakologie $x terapeutické užití $7 D002118
- 650 12
- $a potravní doplňky $7 D019587
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glykosaminoglykany $x metabolismus $7 D006025
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nanočástice $x chemie $7 D053758
- 650 _2
- $a postmenopauzální osteoporóza $x farmakoterapie $x patofyziologie $7 D015663
- 650 _2
- $a poréznost $7 D016062
- 650 _2
- $a Ramanova spektroskopie $7 D013059
- 650 _2
- $a vitamin D $x farmakologie $x terapeutické užití $7 D014807
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gamsjaeger, S $u Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK, AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Heinrich Collin Str. 30, A-1140, Vienna, Austria.
- 700 1_
- $a Hassler, N $u Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK, AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Heinrich Collin Str. 30, A-1140, Vienna, Austria.
- 700 1_
- $a Fahrleitner-Pammer, A $u Dept. of Internal Medicine, Medical University Graz, Austria.
- 700 1_
- $a Dobnig, H $u Thyroid, Endocrinology, and Osteoporosis Institute, Graz, Austria.
- 700 1_
- $a Stepan, J J $u Institute of Rheumatology, Faculty of Medicine 1, Charles University, Prague, Czech Republic.
- 700 1_
- $a Pavo, I $u Endocrinology Dept., Oslo University Hospital, Norway.
- 700 1_
- $a Eriksen, E F $u Endocrinology Dept., Oslo University Hospital, Norway.
- 700 1_
- $a Klaushofer, K $u Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK, AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Heinrich Collin Str. 30, A-1140, Vienna, Austria.
- 773 0_
- $w MED00000833 $t Bone $x 1873-2763 $g Roč. 95, č. - (2017), s. 41-46
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27826025 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521123210 $b ABA008
- 999 __
- $a ok $b bmc $g 1300548 $s 1013764
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 95 $c - $d 41-46 $e 20161105 $i 1873-2763 $m Bone $n Bone $x MED00000833
- LZP __
- $a Pubmed-20180515
